Loading…

Single‐Entity Hydrocodone Extended‐Release Capsules in Opioid‐Tolerant Subjects with Moderate‐to‐Severe Chronic Low Back Pain: A Randomized Double‐Blind, Placebo‐Controlled Study

Objective A single‐agent, extended‐release formulation of hydrocodone (HC) has been developed for treatment of chronic moderate‐to‐severe pain. This study was designed to examine the safety and efficacy of HC extended release in opioid‐experienced adults with moderate‐to‐severe chronic low back pain...

Full description

Saved in:
Bibliographic Details
Published in:Pain medicine (Malden, Mass.) Mass.), 2014-06, Vol.15 (6), p.975-985
Main Authors: Rauck, Richard L., Nalamachu, Srinivas, Wild, James E., Walker, George S., Robinson, Cynthia Y., Davis, Charles S., Farr, Stephen J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective A single‐agent, extended‐release formulation of hydrocodone (HC) has been developed for treatment of chronic moderate‐to‐severe pain. This study was designed to examine the safety and efficacy of HC extended release in opioid‐experienced adults with moderate‐to‐severe chronic low back pain (CLBP). Methods This multicenter, enriched enrollment, randomized withdrawal study comprised an open‐label conversion/titration phase (≤6 weeks) followed by placebo‐controlled, double‐blind treatment (12 weeks). During the conversion/titration phase, subjects (N = 510) converted from their current opioid and were titrated to a stabilized dose of HC extended release (20−100 mg every 12 hours). During treatment, subjects (N = 151 per group) received HC extended release or placebo; rescue medication was permitted. The primary efficacy end point was mean change in average pain intensity from baseline to day 85. Response rates (30% pain improvement) and satisfaction (Subject Global Assessment of Medication) were assessed. Results Demographic and baseline characteristics were similar between groups. Mean ± SD change in average pain intensity score from baseline to day 85 was significantly lower in the HC extended‐release treatment group vs placebo (0.48 ± 1.56 vs 0.96 ± 1.55; P = 0.008). Significantly more responders were in the treatment group (68% vs 31%; P 
ISSN:1526-2375
1526-4637
DOI:10.1111/pme.12377